Global Alliance for TB Drug Development

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

By Therapeutic Area

top 1

Infectious Disease

150%

R&D Momentum

30/100

Pipeline Velocity

6/100

Trial Completion Rate

97/100

Pipeline Concentration

50/100

Pipeline Freshness

85/100

Strategic Signals

↗Active in Infectious Disease but thin pipeline — potential licensing opportunity

Activity

Key Events

Aug 28, 2026TrialAn Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)

Aug 20, 2026TrialA Phase 2b, Randomised, Multi-center, Partially Blinded Trial Assessing the Safety and Efficacy of Regimens Containing Sorfequiline, Pretomanid and Linezolid in Adults With Newly Diagnosed, Drug-sensitive, Smear Positive Pulmonary Tuberculosis

Jun 25, 2026TrialA Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Oct 3, 2025FDAHR — OMEPRAZOLE

Nov 8, 2024FDAHR — OMEPRAZOLE

Sep 19, 2024FDAHR — LANSOPRAZOLE

4 more events

Jan 18, 2024FDAHR — ACETAMINOPHEN

Sep 30, 2022FDAHR — OMEPRAZOLE

Jun 30, 2022TrialA Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Oct 21, 2021FDAHR — OMEPRAZOLE

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Regulatory

Regulatory Timeline

20162 events

FDADec 1

HR — OMEPRAZOLE

Application NDA022032

FDAAug 26

HR — TYLENOL

Application NDA019872

20172 events

FDANov 13

HR — OMEPRAZOLE

Application NDA022032

FDAOct 30

HR — OMEPRAZOLE

Application NDA022032

20194 events

FDAAug 16

HR — ACETAMINOPHEN

Application ANDA075077

FDAApr 16

HR — ACETAMINOPHEN

Application ANDA211544

FDAApr 8

HR — OMEPRAZOLE

Application NDA022032

FDAJan 16

HR — TYLENOL

Application NDA019872

20202 events

FDAAug 20

HR — LANSOPRAZOLE

Application ANDA202319

FDAAug 20

HR — LANSOPRAZOLE

Application ANDA202319

20213 events

FDAOct 21

HR — OMEPRAZOLE

Application NDA022032

FDAAug 25

HR — ACETAMINOPHEN

Application ANDA215486

FDAJul 7

HR — OMEPRAZOLE

Application NDA022032

20221 event

FDASep 30

HR — OMEPRAZOLE

Application NDA022032

20245 events

FDANov 8

HR — OMEPRAZOLE

Application NDA022032

FDASep 19

HR — LANSOPRAZOLE

Application ANDA202319

FDASep 19

HR — LANSOPRAZOLE

Application ANDA202319

FDASep 19

HR — LANSOPRAZOLE

Application ANDA202319

FDAJan 18

HR — ACETAMINOPHEN

Application ANDA211544

20251 event

FDAOct 3

HR — OMEPRAZOLE

Application NDA022032

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)

Global Alliance for TB Drug Development

Pipeline Snapshot

Key Events

Company Info

Drug Pipeline

Infectious Disease

Unknown / Other

Infectious Disease

Unknown / Other

Regulatory Timeline